2m 2m 2m 2m 2m 2m 2m
GAIN THERAPEUTIC (GANX)
NASDAQ
$1.83+$0.04 (+2.12%)
Price as of Jun 03, 2026 6:08 PM EDT- $83.2MMarket Cap
- -10.05%1-Year Change
- BiotechnologyIndustry
GAIN THERAPEUTIC (GANX)
$1.83+$0.04 (+2.12%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 N/A | 0 -100.00% | 55,180 -60.62% | 140,108 -15.08% | |
Cost of Revenue | 0 N/A | 0 N/A | 0 N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 -100.00% | 55,180 -60.62% | 140,108 -15.08% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -10.2M -5.36% | -10.8M -6.33% | -11.5M +37.52% | -8.4M +16.93% | |
Depreciation and Amortization Expense | 94,046 +11.86% | 84,071 +0.59% | 83,579 +30.25% | 64,168 +314.41% | |
Total Operating Expenses | 18.7M -8.06% | 20.4M -8.78% | 22.3M +24.51% | 17.9M +28.06% | |
Operating Profit | -18.7M -8.06% | -20.4M -8.55% | -22.3M +25.18% | -17.8M +28.58% | |
Interest Income | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 244,394 -31.56% | 357,096 -27.75% | 494,234 +31.67% | 375,357 +2,904.06% | |
Income before Taxes | -19.3M -2.89% | -19.9M -10.43% | -22.2M +26.81% | -17.5M +26.00% | |
Income Taxes | 861,118 +60.41% | 536,815 +577.16% | 79,275 -14.74% | 92,976 +2,219.76% | |
Extraordinary Items | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Net Income | -20.2M -1.23% | -20.4M -8.34% | -22.3M +26.59% | -17.6M +26.64% | |
Net Income from Continuing Operations Applicable to Common | -19.3M -2.89% | -19.9M -10.43% | -22.2M +26.81% | -17.5M +26.00% | |
Basic EPS and Net Income | -0.61 -31.46% | -0.89 -47.95% | -1.71 +15.54% | -1.48 +8.03% | |
Diluted EPS and Net Income | -0.61 -31.46% | -0.89 -47.95% | -1.71 +15.54% | -1.48 +8.03% | |
Basic Weighted Average Shares | 33.0M +44.08% | 22.9M +75.86% | 13.0M +9.49% | 11.9M +16.90% | |
Diluted Weighted Average Shares | 33.0M +44.08% | 22.9M +75.86% | 13.0M +9.49% | 11.9M +16.90% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 20.8M +100.63% | 10.4M -11.95% | 11.8M +61.32% | 7.3M -80.17% | |
Short-Term Investments | N/A N/A | 0 -100.00% | 5.0M -61.02% | 12.8M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 20.8M +100.63% | 10.4M -38.16% | 16.8M -16.60% | 20.1M -45.40% | |
Total Current Assets | 22.2M +91.66% | 11.6M -34.74% | 17.8M -15.71% | 21.1M -44.09% | |
Accumulated Depreciation | 183,765 +48.97% | 123,357 +32.93% | 92,797 +74.01% | 53,329 +87.85% | |
Property and Plant and Equipment and Net | 74,916 -27.70% | 103,619 -17.74% | 125,962 -12.76% | 144,379 +36.22% | |
Total Long-Term Assets | 581,837 +11.59% | 521,406 -37.22% | 830,463 -72.39% | 3.0M +138.17% | |
Total Assets | 22.8M +88.22% | 12.1M -34.85% | 18.6M -22.78% | 24.1M -38.18% | |
Income Taxes Payable | 210,982 -14.86% | 247,812 +406.10% | 48,965 -54.37% | 107,311 +28,139.74% | |
Total Short-Term Debt | 100,869 -8.45% | 110,177 -7.26% | 118,797 +9.86% | 108,135 +4.15% | |
Total Current Liabilities | 3.4M -14.29% | 3.9M -20.98% | 4.9M +19.99% | 4.1M +61.61% | |
Total Long-Term Debt | 300,084 -8.60% | 328,327 -26.88% | 449,053 -9.33% | 495,258 -16.12% | |
Total Long-Term Liabilities | 901,831 +3.30% | 872,989 -19.25% | 1.1M -1.23% | 1.1M -32.22% | |
Total Liabilities | 4.3M -11.08% | 4.8M -20.67% | 6.0M +15.54% | 5.2M +25.25% | |
Retained Earnings | -81.2M +33.58% | -60.8M +57.81% | -38.5M +84.06% | -20.9M +197.45% | |
Total Stockholders Equity | 18.6M +152.94% | 7.3M -41.65% | 12.6M -33.38% | 18.9M -45.78% | |
Total Shares Outstanding | 42.1M +55.07% | 27.1M +67.42% | 16.2M +36.38% | 11.9M 0.00% | |
Cash Flow | |||||
Cash from Operating Activities | -18.5M -2.16% | -18.9M +0.04% | -18.9M +28.41% | -14.7M +18.81% | |
Capital Expenditures | 22,493 0.00% | 22,493 +46.46% | 15,358 -87.09% | 118,953 +26.26% | |
Cash from Investing Activities | 5.0M 0.00% | 5.0M -51.31% | 10.2M +169.19% | -14.8M +15,582.52% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 28.4M +118.63% | 13.0M +2.93% | 12.6M +16,147.61% | -78,774 -100.19% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | 100.00% N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | -40,328.26% +217.84% | -12,688.10% N/A | |
Return on Assets | -115.39% -13.12% | -132.83% +27.38% | -104.28% +86.98% | -55.77% N/A | |
Return on Equity | -155.66% -24.05% | -204.95% +44.77% | -141.57% +116.08% | -65.52% N/A | |
Revenue Growth | N/A N/A | -100.00% +64.97% | -60.62% +301.88% | -15.08% N/A | |
Current Ratio | 6.63 +123.61% | 2.97 -17.41% | 3.59 -29.75% | 5.11 N/A | |
Cash Ratio | 6.22 +134.09% | 2.66 +11.44% | 2.38 +34.44% | 1.77 N/A | |
Debt-to-Equity Ratio | 0.02 -63.82% | 0.06 +32.37% | 0.05 +40.94% | 0.03 N/A | |
Debt-to-Assets Ratio | 0.02 -51.38% | 0.04 +18.69% | 0.03 +22.00% | 0.03 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow